Layoffs by 2022

Anyone know if the masterplan of all those post-merger synergy reduction and layoffs by 2022 has any merit or has that fallen off by the wayside? Specifically on the R&D side?

 

Without a doubt, there will be layoffs at BMS as well as the rest of the industry. The over priced housing industry will implode as the economy sags and those who remember 2008 will relive another crash. The pandemic hangover won’t be as catastrophic as 2008, but bad enough to cause financial institutions to protect themselves by foreclosing on the overextended. Beware.

 

well the cuts will be before 2022! Consultants are already looking at this.

 

I guess I was wrong. Hem is expanding. Celgene still rules.

 

You ever hear of the roaring 20s? It occurred right after the pandemic of 1918.

Think positive. I know it is tough at BMS since it is a horrible cult.

 

Do you really think the are just adding heads or taking away from somewhere else?? I guess the latter. Opdivo and Zeposia will take major headcount hits.

 

Who says Zeposia will see cuts? Things are trending up.

 

https://www.fiercepharma.com/marketing/ibd-physician-survey-highly-positive-for-abbvie-s-rinvoq-but-not-so-much-for-bristol

 

The consultants looking at budgets! The company is not going to keep throwing money at a drug that might not break $100 million in sales.

 

BMS should focus on Hem/Onc and dump the other garbage drugs to the companies that are wanting to focus on those specialties.

 

BMS should focus on getting rid of all of the old time BMS employees that keep their toxic culture going.

 

Amen to that!

 

Probably most of the people on this forum who be on the list, looking at the level of most discussions

 

Cardiovascular business unit now larger and higher growth compared to I-O business unit with more to come.

 

amen

 

Gird your loins!

 

Buckle up….the end is near for some

 

Will NEVER understand how or why oncology has pods of multiples But good for them since they can take up hobbies or get a side gig since they have extremely limited if not zero access to prescribers.

 

It has to be the biggest welfare job in pharma